Major R&D Projects:
-
Development of peroxynitrite scavengers (nitroscience™)
-
Development of matrix metalloproteinase (MMP) inhibitors (MMPharma™ Project, see www.mmpharma.com)
- Development of activators of biglycan activity (biglycan™, see www.biglycan.com)
Major R&D Grants:
Technology transfer support of the cardiovascular R&D projects of Pharmahungary.
Baross Gabor program, National Office for Research and Technology, 2009.
Development of “dietary foods for
special medical purposes” for patients suffering from diabetes,
atherosclerosis and coronary
heart disease.
National Technology
Platform (Med-Food project, awarded for the period of 2008-2012)
Platform
of mouse and human embryonic stem cell-derived cardiomyocyte test
systems for drug development.
Jedlik Anyos Grant (ESZHEART
project,
awarded for the period of 2008-2010)
Development of drug
candidates based on
genomics and chemoinformatics against myocardial infarction:
inhibitors
of matrix metalloproteinases. For further information www.mmpharma.com
Jedlik Anyos Grant
(NKFP_06_A1_MMP_2006 project, awarded for the period of 2007-2010)
Modulation
of peroxynitrite-induced
myocardial damage by pharmacological and gene therapies,
and development of clinical applications of peroxynitrite
markers.
(GVOP-331-2004-04-0095_30,
awarded for the period of 2005-2007)
Major Publications of Pharmahungary:
Csonka C, Kupai K, Kocsis GF, Novák G, Fekete V, Bencsik P, Csont T, Ferdinandy P. Measurement of myocardial infarct size in preclinical studies. J Pharmacol Toxicol Methods. (2010) [in press]
Kupai K, Szucs G, Cseh S, Hajdu I, Csonka C, Csont T, Ferdinandy P. Matrix metalloproteinase activity assays: Importance of zymography. J Pharmacol Toxicol Methods. (2010) [in press]
Csont T, Görbe A, Bereczki E, Szunyog A, Aypar E, Tóth ME, Varga ZV, Csonka C, Fülöp F, Sántha M, Ferdinandy P. Biglycan protects cardiomyocytes against hypoxia/reoxygenation injury: Role of nitric oxide. J Mol Cell Cardiol. 2010 Jan 20. [in press]
Kupai K, Csonka C, Fekete V, Odendaal L, van Rooyen J, Marais de W, Csont T, Ferdinandy P. Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postconditioning: role of peroxynitrite. Am J Physiol Heart Circ Physiol. 297:H1729-35 (2009)
Csont T, Ferdinandy P. Letter regarding article "Biglycan is
required for adaptive remodeling after myocardial infarction". Circulation 118:e521 (2008)
Kocsis GF, Pipis J, Fekete V, Kovacs-Simon A, Odendaal L, Molnar E,
Giricz Z, Janaky T, van Rooyen J, Csont T, Ferdinandy P. Lovastatin interferes with the infarct
size-limiting effect of ischemic preconditioning and postconditioning
in rat hearts. Am J Physiol
Heart Circ Physiol 294:H2406-2409 (2008)
Ferdinandy P, Schulz R, Baxter GF. Interaction
of cardiovascular risk factors with myocardial ischemia/reperfusion
injury, preconditioning and postconditioning. Pharmacol Rev 59:418-458 (2007)
Dormán G, Kocsis-Szommer K, Spadoni C, Ferdinandy P. MMP inhibitors in cardiac diseases: an
update.
Recent Patents Cardiovasc Drug Discov 2:186-194 (2007).
Csont T, Bereczki E, Bencsik P, Fodor G, Gorbe A, Zvara A, Csonka C,
Puskas LG, Santha M, Ferdinandy P.
Hypercholesterolemia increases
myocardial oxidative and nitrosative stress thereby leading to cardiac
dysfunction in apoB-100 transgenic mice.
Cardiovasc Res. 76:100-109
(2007)
Papp A, Szommer T, Barna L, Gyimesi G, Ferdinandy P, Spadoni C, Darvas
F, Fujita T, Ürge L, Dormán G. Enhanced
hit-to-lead process using bioanalogous lead evolution and
chemogenomics: application in designing selective matrix
metalloprotease inhibitors. Expert
Opin Drug Discov 2:707-723 (2007)
Bereczki E, Gonda S, Csont T, Korpos E,
Zvara A, Ferdinandy P, Santha M. Overexpression
of biglycan
in the heart of transgenic mice: an antibody microarray study.
J Proteome Res. 6:854-861(2007)
Ferdinandy P. Peroxynitrite: just an
oxidative/nitrosative stressor or a physiological regulator as well?
Br J Pharmacol 148:1-3 (2006).
Turan N, Csonka C, Csont T, Giricz Z,
Fodor G, Bencsik P, Gyongyosi M, Cakici I, Ferdinandy P.
The role of peroxynitrite in chemical
preconditioning with
3-nitropropionic acid in rat hearts.
Cardiovasc Res 70:384-390
(2006)
Br J Pharmacol 147:125-127 (2006)
Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R, Ferdinandy P. Hyperlipidemia attenuates the infarct
size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition.
J Pharmacol Exp Ther 316:154-61(2006)
Ungi I, Ungi T, Ruzsa Z, Nagy E, Zimmermann Z, Csont T, Ferdinandy P. Hypercholesterolemia attenuates
the anti-ischemic effect of preconditioning during coronary angioplasty. Chest 128:1623-1628 (2005)